James Shannon

James Samuel Shannon is currently Chairman at MannKind Corp.
since 2020, Chairman-Supervisory Board at ProQR Therapeutics NV since 2024, Chairman at Impatients NV since 2016, Chairman at Kyowa Kirin Ltd. since 2019, Director at Mytommorows, Independent Director at Xilio Therapeutics, Inc. since 2024, Member at The Royal College of Physicians, and Member-Supervisory Board at Leyden Laboratories BV since 2020.
Former roles include President, Chief Executive Officer & Director at Cerimon Pharmaceuticals, Inc. from 2009 to 2010; Independent Director at MannKind Corp.
from 2011 to 2012; Non-Executive Director at NIOX Healthcare Ltd.; Independent Director at Horizon Therapeutics Ltd. (Ireland) from 2017 to 2023; Director at Biotie Therapies Oy from 2010 to 2012; Director at Xanodyne Pharmaceuticals, Inc.; Independent Director at Endocyte, Inc. from 2010 to 2012; Director at Immodulon Therapeutics Ltd. from 2016 to 2021; Director at Arch Therapeutics, Inc.; Director at ViiV Healthcare Ltd.; Member-Supervisory Board at Crucell NV from 2010 to 2011; Chief Medical Officer at GSK Plc from 2012 to 2015; Senior Vice President-Clinical Development at Sterling Winthrop, Inc. from 1987 to 1994; Head-Drug Regulatory Affairs at Sandoz Ltd. in 1995; and Global Head-Pharmaceutical Development at Novartis Pharma AG from 1994 to 2008.
Education includes undergraduate, graduate, and doctorate degrees from Queen's University of Belfast.